Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease

被引:0
|
作者
Caifang Gao
Lijuan Liu
Yangyang Zhou
Zhaoxiang Bian
Shengpeng Wang
Yitao Wang
机构
[1] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[2] PU-UM Innovative Institute of Chinese Medical Sciences,College of Pharmacy
[3] Guangdong-Macau Traditional Chinese Medicine Technology Industrial Park Development Co.,School of Chinese Medicine
[4] Ltd,Leiden University European Center for Chinese Medicine and Natural Compounds, Institute of Biology
[5] Chengdu University of Traditional Chinese Medicine,undefined
[6] Hong Kong Baptist University,undefined
[7] Leiden University,undefined
来源
关键词
Inflammatory bowel disease; Chinese medicine; Drug delivery system; Ulcerative colitis;
D O I
暂无
中图分类号
学科分类号
摘要
Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed.
引用
收藏
相关论文
共 50 条
  • [21] New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
    Fiorino, G.
    Fries, W.
    De La Rue, S. A.
    Malesci, A. C.
    Repici, A.
    Danese, S.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (17) : 1851 - 1857
  • [22] Hydrogel drug delivery for inflammatory bowel disease
    Megan Cully
    Nature Reviews Drug Discovery, 2015, 14 : 678 - 679
  • [23] A review on curcumin colon-targeted oral drug delivery systems for the treatment of inflammatory bowel disease
    Hossein Shahdadi Sardou
    Paria Rahnama Vosough
    Mohammadreza Abbaspour
    Abbas Akhgari
    Thozhukat Sathyapalan
    Amirhossein Sahebkar
    Inflammopharmacology, 2023, 31 : 1095 - 1105
  • [24] A review on curcumin colon-targeted oral drug delivery systems for the treatment of inflammatory bowel disease
    Sardou, Hossein Shahdadi
    Vosough, Paria Rahnama
    Abbaspour, Mohammadreza
    Akhgari, Abbas
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    INFLAMMOPHARMACOLOGY, 2023, 31 (03) : 1095 - 1105
  • [25] Alternative Medicine Products as a Novel Treatment Strategy for Inflammatory Bowel Disease
    Jackson, Lindsey N.
    Zhou, Yuning
    Qiu, Suimin
    Wang, Qingding
    Evers, B. Mark
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2008, 36 (05): : 953 - 965
  • [27] Oral liposomes as a drug delivery system for the treatment of inflammatory bowel disease.
    Zhou, SY
    Fleisher, D
    Weiner, N
    Zimmermann, EM
    GASTROENTEROLOGY, 1998, 114 (04) : A1124 - A1124
  • [28] Drug delivery strategies in the therapy of inflammatory bowel disease
    Lautenschlaeger, Christian
    Schmidt, Carsten
    Fischer, Dagmar
    Stallmach, Andreas
    ADVANCED DRUG DELIVERY REVIEWS, 2014, 71 : 58 - 76
  • [29] Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies
    Liu, Peng
    Gao, Caifang
    Chen, Hongguo
    Vong, Chi Teng
    Wu, Xu
    Tang, Xudong
    Wang, Shengpeng
    Wang, Yitao
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (09) : 2798 - 2818
  • [30] Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies
    Peng Liu
    Caifang Gao
    Hongguo Chen
    Chi Teng Vong
    Xu Wu
    Xudong Tang
    Shengpeng Wang
    Yitao Wang
    Acta Pharmaceutica Sinica B, 2021, 11 (09) : 2798 - 2818